Abstract
Targeting rare variants of a pan-cancer target: The landscape of <i>BRAF</i> non-v600 mutations and <i>BRAF</i>fusions from 172,005 adult patients with cancer.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
